ZB011(ZB011) - 药物靶点：IGF-1R_在研适应症：格雷夫斯眼病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

靶点

IGF-1R

作用机制

IGF-1R拮抗剂(胰岛素样生长因子-I受体拮抗剂)

治疗领域

免疫系统疾病遗传病与畸形内分泌与代谢疾病+ [1]

在研适应症

格雷夫斯眼病

非在研适应症-

原研机构

上海泽纳仕生物科技有限公司

在研机构

上海泽纳仕生物科技有限公司

非在研机构

Viridian Therapeutics, Inc.

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 ZB011 相关的临床结果

登录后查看更多信息

100 项与 ZB011 相关的转化医学

登录后查看更多信息

100 项与 ZB011 相关的专利（医药）

登录后查看更多信息

1

项与 ZB011 相关的文献（医药）

2012-01-01·Evidence-Based Complementary and Alternative Medicine4区 · 医学

The Tibetan Uterotonic Zhi Byed 11: Mechanisms of Action, Efficacy, and Historical Use for Postpartum Hemorrhage

4区 · 医学

ArticleOA

作者: Morris, Jessica L. ; Stenson, Amy ; Tudor, Carrie ; Coelius, Rebecca Lynn ; Miller, Suellen ; Cuomu, Mingji

Objective. To explore evidence for the traditional Tibetan medicine, Zhi Byed 11 (ZB11), for use as a uterotonic.Methods. The eleven ingredients in ZB11 were chemically analyzed by mass spectroscopy. A review was conducted of Western allopathic literature for scientific studies on ZB11’s individual components. Literature from Tibetan and other traditional paradigms were reviewed.Results. Potential mechanisms of action for ZB11 as a uterotonic include laxative effects, a dose-dependant increase in smooth muscle tissue peristalsis that may also affect the uterus smooth muscle, and chemical components that are prostaglandin precursors and/or increase prostaglandin synthesis. A recent RCT demonstrated comparable efficacy to misoprostol in reducing severe postpartum hemorrhage (PPH) (>1000 mL) and greater effect than placebo. Historical and anecdotal evidence for ZB11 and its ingredients for childbirth provide further support.Discussion. ZB11 and its ingredients are candidates for potentially effective uterotonics, especially in low-resource settings. Further research is warranted to understand the mechanisms of action and synergy between ingredients.

100 项与 ZB011 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
格雷夫斯眼病	临床前	中国	上海泽纳仕生物科技有限公司	2022-05-11
格雷夫斯眼病	临床前	中国	Viridian Therapeutics, Inc.	2022-05-11